Frazier Life Sciences Acquisition Corp. II (NASDAQ:FLSC) Stock Short Interest Report for October

Key Points

• Short interest rose significantly in October to 17,259 shares as of October 15, representing approximately 0.2% of FLSC’s outstanding shares and a days-to-cover ratio of 0.2.
• CEO Albert Cha purchased 300,000 shares for $3 million at $10 per share, substantially increasing his stake in the company.
• FLSC received a “hold” rating from Wall Street Zen, while its shares recently traded at $10.17—within a 52-week range of $10.10 to $10.63. The company is a SPAC seeking a life sciences-sector business combination.

Frazier Life Sciences Acquisition Corp. II (NASDAQ:FLSC - Get Free Report) was the recipient of a large growth in short interest during the month of October. As of October 15th, there was short interest totaling 17,259 shares. Approximately 0.2% of the shares of the company are short sold. Based on an average daily volume of 112,857 shares, the days-to-cover ratio is currently 0.2 days.

Insider Activity at Frazier Life Sciences Acquisition Corp. II

In related news, CEO Albert Cha purchased 300,000 shares of the business's stock in a transaction on Thursday, October 15th. The shares were acquired at an average price of $10.00 per share, for a total transaction of $3,000,000.00. Following the purchase, the chief executive officer owned 300,000 shares of the company's stock, valued at $3,000,000. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Analysts Set New Price Targets

Separately, Wall Street Zen raised shares of Frazier Life Sciences Acquisition Corp. II to a "hold" rating in a report on Saturday, October 24th.

Frazier Life Sciences Acquisition Corp. II Price Performance

FLSC traded down $0.04 during trading on Friday, reaching $10.17. 3,763 shares of the company's stock were exchanged, compared to its average volume of 141,373. Frazier Life Sciences Acquisition Corp. II has a 1 year low of $10.10 and a 1 year high of $10.63.

About Frazier Life Sciences Acquisition Corp. II

Frazier Life Sciences Acquisition Corp. II is a special purpose acquisition company, or SPAC, focused on identifying and combining with a business in the life sciences sector. The company does not operate a conventional commercial business and was formed to pursue a merger, acquisition, or similar business combination.

Its target opportunities may include companies involved in biotechnology, pharmaceuticals, medical devices, diagnostics, or other healthcare-related technologies. The company's objective is to provide a publicly traded platform for a private life sciences business through a business combination.

Frazier Life Sciences Acquisition Corp.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.